Krystal Biotech Inc is trading at $336.98 (+4.21%) after reporting Q1 2026 financial results that surpassed analyst expectations and receiving a price target increase.
- The company reported earnings of $1.83 per share compared to the $1.45 estimate, with revenue also topping forecasts.
- Jefferies raised its price target for the stock to $371, citing continued bullish sentiment following the upbeat earnings report.
- The stock is significantly outperforming the broader market, gaining on company-specific news while the Nasdaq trades slightly lower.